Taro Pharmaceutical Industries Ltd.
TARO · NYSE
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $363 | $382 | $269 | $124 |
| Short-Term Investments | $516 | $520 | $638 | $682 |
| Receivables | $177 | $230 | $227 | $283 |
| Inventory | $205 | $215 | $208 | $205 |
| Other Curr. Assets | $42 | $0 | $0 | $0 |
| Total Curr. Assets | $1,303 | $1,347 | $1,343 | $1,294 |
| Property Plant & Equip (Net) | $218 | $218 | $190 | $190 |
| Goodwill | $17 | $17 | $17 | $17 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $458 | $404 | $388 | $451 |
| Tax Assets | $83 | $97 | $101 | $101 |
| Other NC Assets | $82 | $79 | $81 | $81 |
| Total NC Assets | $859 | $816 | $777 | $841 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $2,162 | $2,163 | $2,119 | $2,135 |
| Liabilities | – | – | – | – |
| Payables | $45 | $51 | $43 | $59 |
| Short-Term Debt | $0 | $0 | $0 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $316 | $323 | $318 | $326 |
| Total Curr. Liab. | $361 | $374 | $361 | $385 |
| LT Debt | $0 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $8 | $10 | $10 | $12 |
| Total NC Liab. | $8 | $10 | $10 | $12 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $369 | $384 | $372 | $397 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $1,793 | $1,779 | $1,748 | $1,739 |
| Retained Earnings | $0 | $0 | $0 | $0 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $0 | $0 | $0 | $0 |
| Total Equity | $1,793 | $1,779 | $1,748 | $1,739 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $2,162 | $2,163 | $2,119 | $2,135 |
| Net Debt | -$363 | -$382 | -$269 | -$124 |